Study record · Thymosin alpha-1
Thymosin alpha-1 versus interferon alpha for chronic hepatitis B: meta-analysis
At end of treatment, thymosin alpha-1 was not clearly superior; at 6-month post-treatment follow-up, pooled virological, biochemical and complete responses.
Key result
At end of treatment, thymosin alpha-1 was not clearly superior; at 6-month post-treatment follow-up, pooled virological, biochemical and complete responses favored thymosin alpha-1.
Study details
Study designMeta-analysis of randomized controlled trials
PopulationPeople with chronic hepatitis B
Sample size199
RouteMixed clinical regimens
Regimen / exposureThymosin alpha-1 versus interferon-alpha across four RCTs
DurationTreatment + 6-month follow-up
ComparatorInterferon-alpha
Primary endpoint / questionVirological, biochemical and complete response
Safety resultSafety was not the main focus of the abstract.
Key limitationsOnly four small RCTs; mostly HBeAg-negative patients; older treatment landscape.
Registry / identifierPMID 18078676